Emilie Gauthy
Chief Technology Officer Zelluna Immunotherapy
Emilie Gauthy joined Zelluna Immunotherapy in November 2022 and serves as Head of CMC (Chemistry, Manufacturing, and Controls). Prior to joining Zelluna, Emilie was Development and Validation Director at Celyad Oncology, leading the development of allogeneic CAR-T cell therapies from research to clinical manufacturing. During her 5 years at Celyad Oncology, she worked on several successful clinical trial applications in the EU and the US and was responsible for CDMO oversight and material selection. Emilie’s previous experiences encompass roles such as Quality Assurance for GSK vaccines development, and Project Management and Quality Control for contract manufacturers. Emilie obtained her PhD from the catholic University of Louvain/de Duve Institute in Brussels in 2013.
Seminars
- Changing the paradigm, from autologous to allogeneic, from single antigen to multiple activation mechanisms, from custom to on-demand
- Current opportunities and challenges of large-scale TCR-NK cells manufacturing
- Approaches to tackle cost-of-goods and increase patient access
New Data
